Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Proxy Fight Looms At Biogen Idec

February 4, 2008 | A version of this story appeared in Volume 86, Issue 5

Claiming flaws in Biogen Idec's recent failed attempt to find a buyer, corporate raider Carl Icahn has nominated three people to fill seats on the biotechnology firm's board of directors. Icahn controls more than 4% of Biogen's stock. Biogen defends its sale process and says it will review Icahn's proposals "in light of the best interests of all shareholders." Icahn also charges that Biogen executives planned to make the firm unattractive to buyers by bidding for a European biotech company. Biogen did not respond to this statement. Shares in Danish antibody developer Genmab rose on Jan. 28 on expectations that Biogen would buy it for $3 billion.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.